Patent 7067551 was granted and assigned to Novartis on June, 2006 by the United States Patent and Trademark Office.
The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.